OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure
Gloria M. Gager, Dirk von Lewinski, Harald Sourij, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 143, pp. 112169-112169
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Gliflozins in the Management of Cardiovascular Disease
Eugene Braunwald
New England Journal of Medicine (2022) Vol. 386, Iss. 21, pp. 2024-2034
Closed Access | Times Cited: 174

Oxidative stress and the role of redox signalling in chronic kidney disease
Seiji Kishi, Hajime Nagasu, Kengo Kidokoro, et al.
Nature Reviews Nephrology (2023) Vol. 20, Iss. 2, pp. 101-119
Closed Access | Times Cited: 93

Applications of SGLT2 inhibitors beyond glycaemic control
Daniel V. O’Hara, Carolyn S.P. Lam, John J.V. McMurray, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 8, pp. 513-529
Closed Access | Times Cited: 26

Acute antiarrhythmic effects of SGLT2 inhibitors–dapagliflozin lowers the excitability of atrial cardiomyocytes
A Paasche, Felix Wiedmann, Manuel Kraft, et al.
Basic Research in Cardiology (2024) Vol. 119, Iss. 1, pp. 93-112
Open Access | Times Cited: 21

The Role of SGLT2-Inhibitors Across All Stages of Heart Failure and Mechanisms of Early Clinical Benefit: From Prevention to Advanced Heart Failure
Simone Pasquale Crispino, Andrea Segreti, Vincenzo Nafisio, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 608-608
Open Access | Times Cited: 2

Cellular senescence and cardiovascular diseases: moving to the “heart” of the problem
Konstantinos Evangelou, Panagiotis Vasileiou, Angelos Papaspyropoulos, et al.
Physiological Reviews (2022) Vol. 103, Iss. 1, pp. 609-647
Open Access | Times Cited: 57

The impact of SGLT2 inhibition on imaging markers of cardiac function: A systematic review and meta-analysis
Panagiotis Theofilis, Alexios S. Antonopoulos, Themistoklis Katsimichas, et al.
Pharmacological Research (2022) Vol. 180, pp. 106243-106243
Closed Access | Times Cited: 39

Molecular Mechanisms and Therapeutic Implications of Endothelial Dysfunction in Patients with Heart Failure
Vasiliki Tsigkou, Evangelos Oikonomou, Artemis Anastasiou, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4321-4321
Open Access | Times Cited: 31

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
Lucia Scisciola, Fatemeh Taktaz, Rosaria Anna Fontanella, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 30

Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging
Ema Schönberger, Vjera Mihaljević, Kristina Steiner, et al.
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 17, pp. 6671-6671
Open Access | Times Cited: 28

Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches
Tatjana Radosavljević, Milica Branković, Janko Samardžić, et al.
Antioxidants (2024) Vol. 13, Iss. 8, pp. 906-906
Open Access | Times Cited: 14

Heart Failure With Preserved Ejection Fraction in the Elderly Population: Basic Mechanisms and Clinical Considerations
Kimia Gharagozloo, Mozhdeh Mehdizadeh, George Heckman, et al.
Canadian Journal of Cardiology (2024) Vol. 40, Iss. 8, pp. 1424-1444
Closed Access | Times Cited: 11

Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy
Ren Jie Phang, Rebecca H. Ritchie, Derek J. Hausenloy, et al.
Cardiovascular Research (2022) Vol. 119, Iss. 3, pp. 668-690
Open Access | Times Cited: 33

SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy
Dominique Croteau, Tomáš Baka, Sara Young, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 160, pp. 114310-114310
Open Access | Times Cited: 13

Oxidative Stress as a Therapeutic Target of Cardiac Remodeling
Danilo Martins, Leonardo Rufino Garcia, Diego Aparecido Rios Queiróz, et al.
Antioxidants (2022) Vol. 11, Iss. 12, pp. 2371-2371
Open Access | Times Cited: 20

Sodium-glucose co-transporter 2 inhibitors: a pleiotropic drug in humans with promising results in cats
Aline Bomfim Vieira, Sarah M. Cavanaugh, Bianca Torres Ciambarella, et al.
Frontiers in Veterinary Science (2025) Vol. 12
Open Access

Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance
Angelica Cersosimo, Nadia Salerno, Jolanda Sabatino, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2

Multifaceted Impact of SGLT2 Inhibitors in Heart Failure Patients: Exploring Diverse Mechanisms of Action
Christos Piperis, Anastasios Marathonitis, Artemis Anastasiou, et al.
Biomedicines (2024) Vol. 12, Iss. 10, pp. 2314-2314
Open Access | Times Cited: 2

Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology
Giorgio Minotti, Pierantonio Menna, Massimiliano Camilli, et al.
Advances in pharmacology (2022), pp. 365-409
Closed Access | Times Cited: 11

Kidneys in heart failure: Impact of flozins
Tomasz Stompór, Agata Winiarska
Kardiologia Polska (2023) Vol. 81, Iss. 11, pp. 1071-1080
Open Access | Times Cited: 6

Association Between the Expression of MicroRNA-125b and Survival in Patients With Acute Coronary Syndrome and Coronary Multivessel Disease
Gloria M. Gager, Ceren Eyileten, Marek Postuła, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 8

Effect of Dapagliflozin on Indicators of Myocardial Fibrosis and Levels of Inflammatory Factors in Heart Failure Patients
Chuanqiang Wang, Yiteng Qin, Xiaojun Zhang, et al.
Disease Markers (2022) Vol. 2022, pp. 1-7
Open Access | Times Cited: 8

Dapagliflozin Alleviates Myocardial Ischaemia Reperfusion Injury by Activating Mitophagy via the AMPK-PINK1/Parkin Signalling Pathway
Wei Zuo, Liang Wang, Ran Tian, et al.
Current Vascular Pharmacology (2023) Vol. 22, Iss. 3, pp. 203-217
Closed Access | Times Cited: 4

Unraveling the Cardiac Matrix: From Diabetes to Heart Failure, Exploring Pathways and Potential Medications
Bogdan-Sorin Tudurachi, Larisa Anghel, Andreea Tudurachi, et al.
Biomedicines (2024) Vol. 12, Iss. 6, pp. 1314-1314
Open Access | Times Cited: 1

Page 1 - Next Page

Scroll to top